, Volume 19, Issue 2, pp 73–79 | Cite as

Plasma and lipoprotein lipid responses to four hypolipid drugs

  • William R. Hazzard
  • Patricia W. Wahl
  • Claude Gagne
  • Deborah Applebaum-Bowden
  • G. Russell Warnick
  • John J. Albers


The responses of 14 hyperlipidemic subjects to 4 hypolipidemic agents were compared by measureing cholesterol and triglyceride in whole plasma, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) monthly for 2 months before and 3 months during treatment with each of 4 drugs: clofibrate, 2 g/d; colestipol, 20 g/d; para-aminosalicylic acid-ascorbate (PAS-C), 6–8 g/d; and oxandrolone, 7.5 mg/d. Lipid responses proved to be stable by the first monthly evaluation both off and on each drug. Mean adherence was high and similar for all agents (81–92% of the prescribed dose). Clofibrate was associated with significant decreases in mean plasma cholesterol (−16%, p<.01), plasma triglyceride (−51%, p<.005), VLDL-cholesterol (−61%, p<.005) and VLDL-triglyceride (−61%, P<.005), while HDL cholesterol increased (+20%, p<.01), and the LDL-cholesterol/HDL ratio declined (−24%, p<.05). Colestipol was associated with decreases in mean plasma cholesterol (−15%, p<.01) and LDL-cholesterol (−22%, p<.05), while VLDL-triglyceride increased (+41%, p<.05), and the LDL-cholesterol/HDL-cholesterol ratio declined (−25%, p<.05). PAS-C was associated with decreases in VLDL-cholesterol (−30%, p<.05), and VLDL-triglyceride (−29%, p<.05), while the LDL-cholesterol/HDL-cholesterol ratio remained unchanged. Oxandrolone was associated with increases in mean plasma cholesterol (+7%, p<.05), LDL-cholesterol (+45%, p<.005 [+25% excluding one subject who increased 298%]), and LDL-triglyceride (+24%, p<.01), while decreases occurred in plasma triglyceride (−31%, p<.05), VLDL-cholesterol (−26%, p<.05), VLDL-triglyceride (−42%, p<.005), HDL-cholesterol (−45%, p<.005), and HDL-triglyceride (−43%, p<.01). The mean LDL-cholesterol/HDL-cholesterol ratio increased by 109% (p<.005), reflecting the reciprocal changes in LDL and HDL. Thus, while both clofibrate and colestipol were associated with significant, equivalent reductions in theoretical atherogenic risk, oxandrolone produced a net effect that was not only adverse but 4 times that magnitude, suggesting caution in its long-term use, even for the management of hypertriglyceridemia.


High Density Lipoprotein Clofibrate Colestipol Lipid Research Clinic Oxandrolone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cheung, M.C., Albers, J.J., Wahl, P.W., and Hazzard, W.R. (1980) Atherosclerosis 35, 215–228.PubMedCrossRefGoogle Scholar
  2. 2.
    Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., and Dawber, T.R. (1977) Am. J. Med. 62, 707–714.PubMedCrossRefGoogle Scholar
  3. 3.
    Brunzell, J.D., Schrott, H.G., Motulsky, A.G., and Bierman, E.L. (1976) Metabolism 25, 313–320.PubMedCrossRefGoogle Scholar
  4. 4.
    Noble, R.P. (1968) J. Lipid Res. 9, 693–700.PubMedGoogle Scholar
  5. 5.
    Fredrickson, D.S., Morganroth, J., and Levy, R.I. (1975) Ann. Int. Med. 82, 150–157.PubMedGoogle Scholar
  6. 6.
    Warnick, G.R., Mayfield, C., Albers J.J., and Hazzard, W.R. (1979) Clin. Chem. 25, 279–284.PubMedGoogle Scholar
  7. 7.
    Lipid Research Clinics Program Manual of Laboratory Operations, (1974) Vol. 1, Lipid and Lipoprotein Analysis, Washington, D.C., US Government Printing Office, DHEW Pub No 75-628.Google Scholar
  8. 8.
    Winer, B.J. (1962) in Statistical Principles in Experimental Design, McGraw-Hill Book Company, New York, Chapter 7.Google Scholar
  9. 9.
    Marascuilo, L.A., and McSweeney, M. (1977) in Nonparametric and Distribution-free Methods for the Social Sciences, pp. 176, Brooks/Cole Publishing Co.Google Scholar
  10. 10.
    Grundy, S.M. (1982) Med. Clin. N. Am. 66, 519–535.PubMedGoogle Scholar
  11. 11.
    Kane, J.P., and Malloy, M.J. (1982) Med. Clin. N. Am. 66, 537–550.PubMedGoogle Scholar
  12. 12.
    Albers, J.J., Cheung, M.C., and Hazzard, W.R. (1978) Metab. Clin. Exp. 27, 479.PubMedGoogle Scholar
  13. 13.
    Breslow, J.L., Spaulding, D.R., Lux, S.E., Levy, R.I., and Less, R.S. (1975) New Eng. J. Med. 293, 900–903.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein, J.L., Dana, S.E., Brunschede, G.Y., and Brown, M.S. (1975) Proc. Natl. Acad. Sci. U.S.A. 72, 1092–1096.PubMedCrossRefGoogle Scholar
  15. 15.
    Brown, M.S., Kovanen, P.T., and Goldstein, J.L. (1981) Science 212, 628–635.PubMedCrossRefGoogle Scholar
  16. 16.
    Utermann, G., Vogelberg, K.H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M., and Canzler, H. (1979) Clin. Genet. 15, 37–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Zannis, V.I., Just, P.W., and Breslow, J.L. (1981) Am. J. Hum. Genet. 3, 11–24.Google Scholar
  18. 18.
    Havel, R.J. (1982) Med. Clin. N. Am. 66, 441–454.PubMedGoogle Scholar
  19. 19.
    Hazzard, W.R., Warnick, G.R., Utermann, G., and Albers, J.J. (1981) Metabolism 30, 79–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Hazzard, W.R., Albers, J.J., Baron, P., Miller, N., Warnick, G.R., and Lewis, B. (1981) Lancet 1, 298–301.PubMedCrossRefGoogle Scholar
  21. 21.
    Wilson, D.E., and Lees, R.S. (1972) J. Clin. Invest. 51, 1051–1057.PubMedCrossRefGoogle Scholar
  22. 22.
    Goldstein, J.L., Hazzard, W.R., Schrott, H.G., Bierman, E.L., and Motulsky, A.G. (1973) J. Clin. Invest. 52, 1544–1568.PubMedGoogle Scholar
  23. 23.
    Boman, H., Hazzard, W.R., Albers, J.J., Cooper, M.N., and Motulsky, A.G. (1975) Am. J. Human Genet. 27, 19A.Google Scholar
  24. 24.
    Oliver, M.R., Heady, J.A., Morris, J.N., and Cooper, J. (1978) Br. Heart J. 40, 1069–1179.Google Scholar
  25. 25.
    Lippel, K., Tyroler, H., Eder, H., Gotto, Jr., A., and Vahouny, G. (1981) Arteriosclerosis 1, 406–417.PubMedGoogle Scholar
  26. 26.
    Brunzell, J.D., and Bierman, E.L. (1982) Med. Clin, N. Am. 66, 455–468.Google Scholar

Copyright information

© American Oil Chemists’ Society (AOCS) 1984

Authors and Affiliations

  • William R. Hazzard
    • 1
  • Patricia W. Wahl
    • 1
  • Claude Gagne
    • 1
  • Deborah Applebaum-Bowden
    • 1
  • G. Russell Warnick
    • 1
  • John J. Albers
    • 1
  1. 1.Northwest Lipid Research Clinic and Departments of Medicine and BiostatisticsUniversity of WashingtonSeattle

Personalised recommendations